Navidea Biopharma (NAVB) Tops Q3 EPS by 1c

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $1.54 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Cantor Fitzgerald Reiterates Overweight Rating on Global Net Lease (GNL)